Abeona Therapeutics Inc. (NASDAQ:ABEO) rose 8.1% during mid-day trading on Monday . The stock traded as high as $3.77 and last traded at $3.75, with a volume of 87,079 shares traded. The stock had previously closed at $3.47.

ABEO has been the subject of several recent research reports. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 28th. Maxim Group reiterated a “buy” rating and set a $6.00 price target on shares of Abeona Therapeutics in a report on Tuesday, August 2nd. Rodman & Renshaw reiterated a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a report on Friday. Finally, FBR & Co reiterated a “buy” rating on shares of Abeona Therapeutics in a report on Wednesday, June 22nd.

The firm’s market capitalization is $120.36 million. The stock’s 50-day moving average price is $2.61 and its 200 day moving average price is $2.66.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.04. Analysts expect that Abeona Therapeutics Inc. will post ($0.66) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC boosted its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned 0.92% of Abeona Therapeutics worth $1,007,000 at the end of the most recent quarter.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.